In a World View commentary published in Nature Medicine on 23 September 2026, Alexandra Kautzky‑Willer argues that sex and gender differences should be an explicit component of clinical treatment guidelines. The author contends that guidelines ought to do more than issue recommendations; they should also document the current evidence base relating to sex and gender, identify where evidence is lacking, and outline what future research must report to close those gaps.
The article presents a procedural recommendation for guideline development: make transparent the degree to which recommendations apply across sexes and genders and describe the limitations of the supporting evidence. This position is framed as a contribution to improving clinical applicability and promoting research that fills identified deficits in knowledge.
Kautzky‑Willer’s central point is that treatment guidelines should clearly state two elements: first, what is already known regarding differences by sex and gender; and second, where evidence is missing. By doing so, guideline users—clinicians, researchers, and policy makers—can better interpret the applicability of recommendations to diverse patient groups.
The commentary emphasizes transparency in guideline reporting rather than prescribing a specific methodological approach or a checklist. It underscores the informational role of guidelines: they should not only advise on treatment choices but also communicate the strength and scope of evidence, including whether outcomes were assessed separately by sex or gender and whether subgroup analyses are reliable.
The author frames this as a necessary step to reduce uncertainty in clinical decision making and to highlight priorities for future research. The recommendation implies that a guideline statement limited to a universal recommendation, without clarifying evidence coverage by sex and gender, risks overlooking clinically relevant differences or perpetuating knowledge gaps.
A core recommendation in the commentary is that guidelines should specify what future clinical trials and reports must include with respect to sex and gender. Although the article does not provide a prescriptive list of reporting items, it calls for guideline panels to set expectations about trial reporting so that subsequent evidence can be directly informative for sex‑ and gender‑specific care.
By asking guideline authors to articulate reporting requirements, the commentary links guideline development with research design and publication practices. The intent is to encourage trialists and journals to adopt reporting that enables pooled assessment and subgroup evaluation by sex and gender, thereby strengthening the evidence available for future guideline updates.
This stance treats guideline documents as drivers of research priorities: when guideline panels declare specific evidence gaps and reporting standards, they create clearer targets for investigators and funders who design and evaluate clinical studies.
The article is authored by Alexandra Kautzky‑Willer of the Division of Endocrinology and Metabolism, Medicine 3, Medical University Vienna, General Hospital Vienna, Austria. It appears as a World View piece in Nature Medicine and was published on 23 September 2026.
The author declares no competing interests. The article is presented as a preview of subscription content on the Nature website; full access may require institutional subscription or individual purchase. The commentary cites a small number of recent publications as supporting context; however, detailed evidence or extended data are not provided within the short World View format.
The piece cites several references, including items published in the European Heart Journal and a 2026 article by the author. Specific reference identifiers are listed in the article’s reference section. The author’s competing‑interest statement indicates no declared conflicts.
Readers interested in the primary studies or in the details of evidence gaps noted by the author will need to consult the referenced literature or the full text where available. The commentary’s principal contribution is a policy and reporting recommendation: make sex and gender differences explicit in guideline content, identify missing evidence, and require that future trials report data to address those gaps.